Precigen announces long-term follow-up results highlighting ongoing durable complete responses after treatment with Papzimeos (zopapogene imadenovec-drba) , the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis
Precigen Inc. announced long-term follow-up data demonstrating durable responses to Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). These data were presented at… read more.
